



NEONATAL MEDICATION PROTOCOLS

ROTAVIRUS VACCINE (RotaTeq)
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	ROTAVIRUS VACCINE (RotaTeq)
PRESENTATION:	2mL : Liquid in squeezable plastic, latex free dosing tube
ACTION & INDICATION:	Live oral pentavalent reassortant vaccine that induces protective immunity against human rotavirus gastroenteritis and it's complications.
DOSE:	Vaccination course of three doses: 1 st dose: between 6 and <13 weeks of age 2 nd and 3 rd dose: at greater than, or equal to 4 week intervals 3 rd dose by <33 weeks of age. To be administered on the day of their discharge from hospital only to infants who have been immunised
ADMINISTRATION:	ORAL: Twist off cap on tube. Administer the entire contents of the dosing tube orally. Do not dilute contents of tube. DO NOT INJECT Observe infant for 15 minutes post administration for anaphylaxis (The dose may be given within the nursery confines)
ADVERSE EFFECTS:	Diarrhoea, vomiting, pyrexia, urticaria, nasopharyngitis Intussusception (very rare) Contraindications: Hypersensitivity to first dose Precautions: Immunosuppression, HIV infection, products including Ig within 42 days, immunodeficient household members, Serious medical conditions eg cystic fibrosis, failure to thrive, congenital heart disease, neutropenia, active GI illness, growth retardation, febrile illness
COMMENTS:	Refrigerate do not freeze. Vaccine should be discarded in approved biological waste if not used within 48 hours of removing from the refrigerator.
REFERENCES:	West Australian Vaccination Schedule August 2013 Product Information
DATE:	October 2013